|Bid||139.69 x 100|
|Ask||144.10 x 100|
|Day's Range||141.92 - 143.51|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||61.98|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.
ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.
Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.